Last reviewed · How we verify

NCT05952466

Retinal and Choroidal Microvascular Parameters in School-age Children in a COVID-19 Infection Pandemic Peak in China

Completed Last updated 19 July 2023
What this trial tests

trial in COVID-19 Pandemic in 100 participants. Completed in 31 March 2023.

Timeline
1 February 2023
Primary endpoint
31 March 2023
31 March 2023

Quick facts

Lead sponsorGuangzhou First People's Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment100
Start date1 February 2023
Primary completion31 March 2023
Estimated completion31 March 2023
Sites1 location across China

Conditions studied

Sponsor

Guangzhou First People's Hospital

Who can join

Adults 6 to 18, any sex, with COVID-19 Pandemic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

We designed this study to examine whether COVID-19 infection could lead to retinal and choroidal microvascular involvement in school-age children (6-18 years) in a pandemic peak in China.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for COVID-19 Pandemic

Currently open trials in the same condition.

Other Guangzhou First People's Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05952466.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing